Yunnan Baiyao Group Co.,Ltd: history, ownership, mission, how it works & makes money

From its founding in Kunming in 1971 to becoming the first Yunnan-listed company on the Shenzhen Stock Exchange in 1993, Yunnan Baiyao Group Co., Ltd. has grown into a diversified pharmaceutical and health-products powerhouse-reporting CNY 40 billion in revenue in 2025 (a 2.4% year‑over‑year rise) with net income of CNY 4.75 billion (up 16%), while tracing a track record that includes RMB 22.6 billion revenue in 2016 and a Fortune China 500 placement at 357 in 2018; today the company's aerosol sprays, plasters, medicated bandages, toothpaste and Panax notoginseng extracts lead their categories, its Pharmaceutical, Health Products, TCM Resources and Pharmaceutical Commerce groups underpin diversified sales, and a concentrated ownership structure-29% held by state and individual investors, 35% by private companies, with the top three shareholders controlling 58%-coexists with strategic moves like the 2022 Huawei AI drug collaboration, a 2024 carbon footprint reduction of 20%, CNY 200 million in health-education funding, a 90.09% payout ratio for 2024 net profit, a special dividend scheduled for 24 September 2025, roughly 9,277 employees as of 2025, R&D centers across Kunming, Beijing, Shanghai, Tianjin and Wuxi, and expanding international sales that together explain how Yunnan Baiyao converts its TCM heritage and modern innovation into multiple revenue streams.

Yunnan Baiyao Group Co.,Ltd (000538.SZ): Intro

• 1971 - Founded in Kunming, China, as a comprehensive enterprise integrating pharmaceutical production and trade.
• 1993 - Became the first company in Yunnan province listed on the Shenzhen Stock Exchange (000538.SZ), accelerating capital access and expansion.
• 2016 - Reported revenue of RMB 22.6 billion, reflecting significant market expansion across pharmaceuticals and consumer health products.
• 2018 - Ranked 357th on the Fortune China 500 List, confirming its position among China's leading enterprises.
• 2024 - Maintained leading market shares in aerosol sprays, plasters, medicated bandages, toothpaste, and Panax notoginseng extracts.
• 2025 - Achieved revenue of CNY 40.0 billion (up 2.4% YoY) and net income of CNY 4.75 billion (up 16% YoY).

• Traditional Chinese medicine (TCM) formulations - signature Yunnan Baiyao powder and derived extracts (Panax notoginseng).
• OTC consumer healthcare - plasters, medicated bandages, topical sprays, toothpaste and wound-care products.
• Prescription pharmaceuticals - hospital-facing TCM and modern medicines, surgical hemostatics and specialty formulations.
• Healthcare distribution and retail - supply chain, pharmacies and e-commerce channels supporting brand reach.

• Listed entity: Yunnan Baiyao Group Co.,Ltd (000538.SZ) - publicly traded with a mix of institutional and retail shareholders.
• Controlling/major shareholder structure historically dominated by group-level holdings and state-linked investors (typical in large Chinese industrial/health groups), with independent directors and established board committees consistent with Shenzhen exchange requirements.

• R&D & product development: combines traditional TCM expertise (notoginseng, herbal formulas) with modern pharmaceutical development and quality control.
• Manufacturing: vertically integrated production of oral formulations, topical products, sterile and non-sterile dosage forms across multiple GMP-certified facilities.
• Distribution & sales: multi-channel distribution - hospitals, wholesalers, retail pharmacies, proprietary stores, and growing e-commerce presence.
• Brand & IP: strong consumer recognition for core products (e.g., Baiyao-branded wound care and toothpaste) and protection of product formulas and trademarks.

• Product sales: dominant revenue from OTC consumer products (plasters, sprays, toothpaste) and hospital/specialty pharmaceuticals (hemostatics, TCM extracts).
• Margin mix: higher-margin branded consumer products and extracts vs. lower-margin distribution/wholesale volumes.
• Geographic expansion: domestic penetration across China plus selective exports for specialty TCM products.
• Channel diversification: rising contribution from e-commerce and direct-to-consumer channels improving gross margin and customer data capture.

Yunnan Baiyao Group Co.,Ltd (000538.SZ): History

• Ownership structure (as of 2024): state and individual investors - 29%; private companies - 35%; remaining shares held by other institutional and retail investors.
• Concentration: the three largest shareholders collectively own 58% of the company's shares, indicating tight control and potential influence on corporate decisions.
• Workforce: approximately 9,277 employees as of 2025.

• How it makes money: core revenue streams include prescription and OTC TCM pharmaceuticals, health products and supplements, medical devices, and consumer healthcare goods leveraging brand recognition and an expansive distribution network.
• How it works: R&D (including AI partnerships), manufacturing, and nationwide distribution; strategic asset allocation and dividend policies reflect strong cash generation and shareholder-return emphasis.

Yunnan Baiyao Group Co.,Ltd (000538.SZ): Ownership Structure

• Integrate traditional Chinese medicine (TCM) with modern healthcare to become a leading domestic and global modern pharmaceutical group.
• Emphasis on innovation - strategic moves into AI-driven drug development (notably a 2022 partnership with Huawei).
• Commitment to sustainability - target of a 20% reduction in carbon footprint by 2024.
• Social responsibility - allocated CNY 200 million to health education programs.
• Shareholder-friendly returns - high dividend payout ratio: 90.09% of 2024 net profit distributed to shareholders.
• Active promoter of the 'TCM + Big Health' strategy under China's 14th Five‑Year Plan (2021-25).

• Core business: development, manufacturing and sales of TCM pharmaceuticals, healthcare products, and consumer health goods.
• R&D + digital transformation: collaboration with Huawei (2022) to apply AI and big data to accelerate drug discovery and optimize manufacturing.
• Sustainability and CSR investments support brand and market access - e.g., energy efficiency and community health programs funded from operating cash flow.
• Revenue mix (2024) is weighted toward pharmaceuticals, with growing contribution from 'Big Health' services and consumer wellness.

• Major controlling & strategic shareholders and free float determine governance and capital access.

• Major R&D and digitalization investments (AI drug discovery with Huawei) to lift long‑term margins and product pipeline value.
• Large dividend policy remains a capital-allocation signal: 90.09% payout of 2024 profit (CNY 1.081 billion) while sustaining strategic investments.
• Sustained public-good spending (CNY 200 million) strengthens brand and regulatory goodwill under the 'TCM + Big Health' push.

Yunnan Baiyao Group Co.,Ltd (000538.SZ): Mission and Values

• Founded on the Yunnan Baiyao patented formulas, the company has evolved from a single flagship hemostatic product into a diversified healthcare group.
• Core product categories emphasize hemostasis, analgesia, anti-swelling and blood-stasis management alongside consumer health and oral-care lines.
• Strategic vertical integration secures raw-material supply, extraction capabilities, manufacturing scale and distribution access.

• Pharmaceutical Business: Primary focus on prescription and OTC medicines addressing hemostasis, analgesia, swelling reduction and stasis-leveraging the Yunnan Baiyao brand and derivative formulations.
• Health Products: Consumer-facing lines including oral care (notably Yunnan Baiyao Toothpaste), nutritional supplements and daily health care items. Yunnan Baiyao Toothpaste holds the leading all-channel market share in China's branded toothpaste segment (by value and multi-channel retail penetration in recent reporting periods).
• Traditional Chinese Medicine Resources: Controls cultivation, procurement, plant extraction, import/export of medicinal materials and terminal operations for supply-chain security and quality control.
• Pharmaceutical Commerce: Distribution, channel partnerships and logistics cooperation with other pharmaceutical entities to expand reach into hospitals, retail pharmacies and e-commerce platforms.

• Five major R&D centers: Kunming, Beijing, Shanghai, Tianjin and Wuxi-focused on TCM research, modern drug development, formulation upgrades, product registration and industrialization.
• R&D investment run-rate: company-reported R&D expenditure accounted for roughly 3-5% of annual revenue in recent fiscal years (reflecting ongoing pipeline development and product improvement initiatives).

• Flagship medicine sales: Hemostatic and related TCM formulations sold through hospitals, clinics and retail pharmacies drive stable high-margin revenue.
• Branded consumer products: Strong brand equity in oral care and health supplements generates volume and multi-channel retail sales (offline + e-commerce).
• Vertical integration: Owning medicinal-material supply and extraction capacity reduces input volatility and secures quality, improving margins.
• Channel partnerships and commerce: Third-party distribution agreements, pharmacy chains and hospital supply contracts expand market penetration and recurring purchases.
• Licensing, export and manufacturing services: Income from extract sales, contract production and international exports contributes to diversification.

• Brand strength: Yunnan Baiyao is among the most recognizable TCM brands in China, enabling premium pricing and cross-selling.
• Portfolio breadth: Combination of prescription, OTC, consumer and raw-material businesses smooths revenue cyclicality.
• R&D pipeline: Ongoing modernization of TCM formulas and new formulation launches supported by multiple R&D centers.
• Supply security: Control over TCM resources mitigates raw-material shortages and regulatory compliance risks.

Yunnan Baiyao Group Co.,Ltd (000538.SZ): How It Works

• Core revenue drivers: sale of pharmaceutical products, health products, and traditional Chinese medicine resources.
• Flagship SKUs: Yunnan Baiyao Aerosol (top retail market share among topical aerosols for joint and muscle pain) and Yunnan Baiyao Toothpaste (consistently leading Chinese market in all‑channel market share).
• Diversified portfolio: health foods, medical devices, personal care items and consumer packaged goods to broaden revenue streams and reduce reliance on a single product line.

• Product sales (domestic retail & hospital procurement): finished pharmaceuticals, OTC medicines, topical aerosols, toothpastes, health supplements.
• Channel mix: traditional pharmacies, hospital tenders, supermarket/CPG channels, e‑commerce platforms (Tmall, JD), and direct sales/dispensaries.
• Export sales: established presence in Southeast Asia and selected European markets - incremental revenue from international retail and distributor agreements.
• Licensing, co‑development and contract manufacturing: monetizing IP and production capacity for third parties.
• Value‑added services: clinical and R&D partnerships, branded marketing, and franchise/agency relationships in overseas markets.

• Pharmaceuticals & TCM formulations - highest single contributor: branded finished drugs and hospital/retail OTC supply; benefits from strong brand premiums and pricing power.
• Consumer health & personal care - toothpaste, topical aerosols, health foods: high turnover, national distribution and strong margin due to brand recognition.
• Medical devices & supplies - growing but smaller margin profile; supports hospital channel penetration.
• Other (licensing, raw material supply, exports) - contributes stable incremental revenue and hedges domestic demand cycles.

• Brand strength and SKU dominance - allows premium shelf placement and promotional leverage.
• Integrated manufacturing network - scales production, reduces COGS and enables contract manufacturing income.
• Channel diversification - retail, hospital procurement and e‑commerce provide resilience against single‑channel shocks.
• R&D and product innovation - ongoing development of new formulations, line extensions and health‑food combinations to expand TAM.
• International expansion - distributor partnerships and localized registrations in Southeast Asia and Europe to lift top‑line growth.

Yunnan Baiyao Group Co.,Ltd (000538.SZ): How It Makes Money

• Core revenue streams: branded finished drugs (prescription and OTC), health supplements and consumer health products, medical consumables and ancillary healthcare services.
• Channel mix: retail pharmacies, hospital procurement, e-commerce, and direct-to-consumer marketing; growing institutional sales via hospitals and healthcare partners.
• Value drivers: strong brand equity in TCM, full-chain cultivation and processing of herbal resources, and rising demand for integrated 'TCM + Big Health' solutions under national policy support.

• Finished TCM pharmaceuticals: 45% (~RMB 9.9bn)
• Consumer health & personal care: 25% (~RMB 5.5bn)
• Medical devices & consumables: 15% (~RMB 3.3bn)
• TCM raw materials & processing services: 10% (~RMB 2.2bn)
• Other/licensing and services: 5% (~RMB 1.1bn)

• Market position: One of China's best-known TCM brands with strong retail recognition and hospital penetration; listed as 000538.SZ.
• Growth focus: Diversification into the broader healthcare market (big-health consumer products, medical consumables, digital health services) to smooth cyclicality of single-product reliance.
• 14th Five-Year alignment: Actively promoting 'TCM + Big Health' per national policy (2021-2025), leveraging favorable regulatory and reimbursement trends.
• Scale and quality targets: Management guidance targets coordinated growth across scale, product structure and quality to evolve into a domestic leader and world-class modern pharmaceutical group.

• Full industrial chain: investments in cultivation bases, standardised planting, primary processing and distribution to secure TCM supply and traceability.
• Technology adoption: use of satellite imaging for cultivated herb monitoring, AI-assisted procurement and supply forecasting, and digital traceability to improve quality certification and credibility of TCM inputs.
• Vertical integration benefits: higher margin capture, improved yield control, and reduced raw-material price volatility through in-house planting and long-term supplier partnerships.

• Premiumization: upsell via higher-value formulations, cross-selling of health products and brand extensions to increase ASP (average selling price).
• Channel shift: expanding e-commerce and direct channels to raise gross margins and reach younger consumers.
• R&D and M&A: sustained R&D spend (~4% of revenue) and selective acquisitions to add pipeline, broaden product mix and accelerate entry into medical devices and services.